个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhong Xiaorong[1] ; Chen Ping[2] ; He Ping[1] ; Wu Yanqi[1] ; Suo Jiaojiao[1] ; Zhu Kunrui[1] ; Yan Xi[1] ; Tian Tinglun[1] ; Yang Qing[3,*1] ; Luo Ting[4,*2] ;
机构： [1]Breast Disease Center, Cancer Center, West China Hospital, Sichuan University,Chengdu, China [2]Nursing Department, Sichuan Clinical Research Center for Cancer, Sichuan CancerHospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of Universityof Electronic Science and Technology of China, Chengdu, China
出处：
DOI： 10.1016/j.clbc.2023.09.011
ISSN：

关键词： Tamoxifen Exemestane Ovarian function suppression

摘要：
Endocrine therapy combined with ovarian function suppression (OFS) is recommended in intermediate- or high-risk patients among premenopausal women with hormone receptor-positive early breast cancer. However, in China, the cost-effectiveness of this strategy compared with endocrine therapy alone is unclear. This study aimed to evaluate the long-term cost-effectiveness of tamoxifen (TAM), TAM+OFS, and exemestane plus OFS (EXE+OFS).On the basis of prognostic data from the Suppression of Ovarian Function Trial (SOFT), cost data from the Hospital Information System of the West China Hospital of Sichuan University, and health utility values from the published literature, a Markov model was established. The incremental cost-effectiveness ratio (ICER) was used to compare the treatment strategies.In a 25-year simulation of adjuvant therapy in Chinese women with early breast cancer, the total costs of TAM, TAM+OFS, and EXE+OFS were $7821, $9318, and $9445, respectively. The quality-adjusted life-years (QALYs) were 11.615, 11.896, and 11.734 years, respectively. Compared with TAM, the ICERs of TAM+OFS and EXE+OFS were $5,327.4021/QALY and $13,647.0588/QALY, respectively. The ICERs of TAM+OFS and EXE+OFS were below the threshold of $32,517/QALY. The reliability and stability of the simulation results were verified using Monte Carlo simulation and sensitivity analysis.In the context of limited resources in China, TAM+OFS and EXE+OFS are cost-effective options compared with TAM.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

基金：
This research was supported by the National Key Development Plan for Precision Medicine Research (Grant No.2017YFC0910004); Foundation of Department of Science andTechnology of Sichuan Province (Grant Number: 20ZDYF1878);Key Research and Development Project of Science and Technology Department of Sichuan Province (Grant number:00402053A2231); the 135 projects for disciplines of excellence, West China Hospital, Sichuan University (grant number:ZYGD18012, ZYJC21035).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Breast Disease Center, Cancer Center, West China Hospital, Sichuan University,Chengdu, China
共同第一作者：
通讯作者：
通讯机构： [*1]Nursing Department, Sichuan ClinicalResearch Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technologyof China, No. 55, Section 4, Renmin South Road, Wuhou District, Chengdu, SichuanProvince, China [*2]Breast Disease Center, Cancer Center,West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu, Sichuan,China
推荐引用方式(GB/T 7714)：
Zhong Xiaorong,Chen Ping,He Ping,et al.Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China[J].CLINICAL BREAST CANCER.2024,24(2):e41-e50.doi:10.1016/j.clbc.2023.09.011.
APA：
Zhong Xiaorong,Chen Ping,He Ping,Wu Yanqi,Suo Jiaojiao...&Luo Ting.(2024).Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China.CLINICAL BREAST CANCER,24,(2)
MLA：
Zhong Xiaorong,et al."Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China".CLINICAL BREAST CANCER 24..2(2024):e41-e50

相关文献

[1]Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China [2]Tamoxifen enhances stemness and promotes metastasis of ERα36+ breast cancer by upregulating ALDH1A1 in cancer cells. [3]Tamoxifen inhibits ER-negative breast cancer cell invasion and metastasis by accelerating Twist1 degradation. [4]A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer [5]Prognostic value of progesterone receptor status in Chinese breast cancer patients treated with tamoxifen [6]Prognostic value of progesterone receptor status in Chinese breast cancer patients treated with tamoxifen [7]CYP2D6多态性与乳腺癌患者他莫昔芬疗效的相关性 [8]原发性肝癌雌激素受体表达及内分泌治疗 [9]F-box and leucine-rich repeat protein 16 controls tamoxifen sensitivity via regulation of mitochondrial respiration in estrogen receptor-positive breast cancer cells [10]Endocrine therapy inhibits proliferation and migration, promotes apoptosis and suppresses survivin protein expression in colorectal cancer cells

资源点击量：43370 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号